HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance66% confidence

Investigational New Drug (IND) Application

Source: FDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Amphastar Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

Get to know the investigational new drug application (IND). This includes the types, laws and regulations, and emergency use of INDs.

Supporting Context

Therapeutic area
Neurology · Opioid Overdose
Sub-indication
Pain

Related signal: FDA Approves Supplemental Application for REXTOVY by Amphastar Pharmaceuticals

Source

View source document

Related Signal

Open signal — FDA Approves Supplemental Application for REXTOVY by Amphastar Pharmaceuticals
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.